Global Companion Diagnostics Market Size study & Forecast, by Technology (Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Real-time PCR (RT-PCR), Gene Sequencing and Other Technologies) by Indication (Lung Cancer,

Global Companion Diagnostics Market Size study & Forecast, by Technology (Immunohistochemistry (IHC), Polymerase Chain Reaction (PCR), In-situ Hybridization (ISH), Real-time PCR (RT-PCR), Gene Sequencing and Other Technologies) by Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma and Other Indications), By End User (Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Others)and Regional Analysis, 2022-2029

Global Companion Diagnostics Market is valued at approximately USD 6.80 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 11.0% over the forecast period 2022-2029. A companion diagnostic is a test used to ensure the usage of a comparable biological product or medication is both safe and effective. These tests are typically used to diagnose cancer. In this, an appropriate medicine is recommended based on the identified biomarker. Based on a particular patient's response, these tests offer personalized treatment. The Companion Diagnostics market is expanding because of factors such as the increasing incidence of Cancer and rising Regulatory Approvals of New Tests for Different Indications.

The rising prevalence of cancer globally is fostering market growth, according to statistics published by the World Health Organization (WHO) in February 2022, approximately 400,000 children develop cancer worldwide every year. Also, according to the statistics published by the World Cancer Research Fund International, in 2020, there were 18,094,716 million cases of cancer diagnosed globally. The International Agency for Research on Cancer estimated increase in the worldwide burden of cancer is to 27.5 million new cases by 2040. The usage of these tests is increasing due to the increased incidence of cancer worldwide, which is boosting the market's expansion. Also, it is anticipated that regulatory approvals of these tests for various indications will expand the market. For instance, in August 2022, the U.S. FDA approved Thermo Fisher Scientific Inc.'s Oncomine Dx Target Test as a companion diagnostic (CDx). This test identifies non-small cell lung cancer tumours that exhibit HER2 (ERBB2) activating mutations (SNVs & Exon 20 Insertion). In addition, the co-development of drug and diagnostic technology and favorable government support is creating lucrative growth in the market. However, the high cost of drug development and associated clinical trials may halt market growth.

The key regions considered for the Global Companion Diagnostics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the rising drug discovery activities, rising prevalence of diseases and rising regulatory approvals in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising disease prevalence, an increase in the number of collaborations for drug development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
Abbott Laboratories
Agilent Technologies Inc.
F.Hoffmann-La Roche Ltd
Biomerieux SA
Qiagen NV
Siemens Healthcare Gmbh
Thermo Fisher Scientific Inc.
Danaher Corporation (Beckman Coulter Inc.)
Almac Group
Illumina Inc.

Recent Developments in the Market:
 In January 2022, Amoy Diagnostics Co. Ltd., and PREMIA Holdings (HK) Limited introduced the AmoyDx Pan Lung Cancer PCR Panel (the ""PLC Panel"") in Japan as a reimbursed companion diagnostic for various anti-cancer drugs.
 In January 2021,In partnership with OmniSeq Corporation, Laboratory Corporation of America Holdings unveiled OmniSeq INSIGHTsm, a complete tissue-based test for genomic and immunological profiling that makes use of next-generation sequencing (NGS) technology. By advancing precision oncology, the test hopes to enhance patient outcomes..

Global Companion Diagnostics Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Technology, Indication, End User Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Technology offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Technology:
Immunohistochemistry (IHC)
Polymerase Chain Reaction (PCR)
In-situ Hybridization (ISH)
Real-time PCR (RT-PCR)
Gene Sequencing
Other Technologies

By Indication:
Lung Cancer
Breast Cancer
Colorectal Cancer
Leukemia
Melanoma
Other Indications
By End User:
Pharmaceutical & Biopharmaceutical Companies
Reference Laboratories
CROs
Others

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned
Abbott Laboratories
Agilent Technologies Inc.
F.Hoffmann-La Roche Ltd
Biomerieux SA
Qiagen NV
Siemens Healthcare Gmbh
Thermo Fisher Scientific Inc.
Danaher Corporation (Beckman Coulter Inc.)
Almac Group
Illumina Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.